cerliponase alfa CAS NO.151662-36-1

We provide customized and high-quality cerliponase alfa product for your project.

Cerliponase alfa, known as Brineura, is an enzyme replacement therapy for Batten disease. In April 2017, Brineura was approved by FDA to slow loss of walking ability in symptomatic children over three years old with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), tripeptidyl peptidase 1 (TPP1) deficiency.